Bioengineered Non-coding RNA Agent (BERA) in Action

Overview

Journal Bioengineered

Date 2016 Jul 15

PMID 27415469

Citations 18

Authors

Zhijian Duan

Ai-Ming Yu

Affiliations

Soon will be listed here.

Abstract

Non-coding RNAs (ncRNAs) including microRNAs (miRNAs) and small interfering RNAs (siRNAs) are important players in the control of gene regulation and represent novel promising therapeutic targets or agents for the treatment of various diseases. While synthetic ncRNAs are predominately utilized, the effects of excessive artificial modifications on higher-order structures, activities and toxicities of ncRNAs remain uncertain. Inspired by recombinant protein technology allowing large-scale bioengineering of proteins for research and therapy, efforts have been made to develop practical and effective means to bioengineer ncRNA agents. The fermentation-based approaches shall offer biological ncRNA agents with natural modifications and proper folding critical for ncRNA structure, function and safety. In this article, we will summarize current recombinant RNA platforms to the production of ncRNA agents including siRNAs and miRNAs. The applications of bioengineered ncRNA agents for basic research and potential therapeutics are also discussed.

Citing Articles

Inhibition of iRhom1 by CD44-targeting nanocarrier for improved cancer immunochemotherapy.

Luo Z, Huang Y, Batra N, Chen Y, Huang H, Wang Y Nat Commun. 2024; 15(1):255.

PMID: 38177179 PMC: 10766965. DOI: 10.1038/s41467-023-44572-6.

RNA-based drugs and regulation: Toward a necessary evolution of the definitions issued from the European union legislation.

Guerriaud M, Kohli E Front Med (Lausanne). 2022; 9:1012497.

PMID: 36325384 PMC: 9618588. DOI: 10.3389/fmed.2022.1012497.

Bioengineered miR-34a modulates mitochondrial inner membrane protein 17 like 2 (MPV17L2) expression toward the control of cancer cell mitochondrial functions.

Yi W, Tu M, Yu A, Lin J, Yu A Bioengineered. 2022; 13(5):12489-12503.

PMID: 35579419 PMC: 9276019. DOI: 10.1080/21655979.2022.2076399.

Non-coding RNAs and their bioengineering applications for neurological diseases.

Das T, Das T, Khodarkovskaya A, Dash S Bioengineered. 2021; 12(2):11675-11698.

PMID: 34756133 PMC: 8810045. DOI: 10.1080/21655979.2021.2003667.

Baicalin suppresses lung cancer growth phenotypes via miR-340-5p/NET1 axis.

Zhao F, Zhao Z, Han Y, Li S, Liu C, Jia K Bioengineered. 2021; 12(1):1699-1707.

PMID: 33955315 PMC: 8806212. DOI: 10.1080/21655979.2021.1922052.

References

Ponchon L, Beauvais G, Nonin-Lecomte S, Dardel F . A generic protocol for the expression and purification of recombinant RNA in Escherichia coli using a tRNA scaffold. Nat Protoc. 2009; 4(6):947-59. DOI: 10.1038/nprot.2009.67. View

Pitulle C, Hedenstierna K, Fox G . Useful properties of restriction enzymes that recognize interrupted palindromes. Biotechniques. 1996; 21(4):619-20, 622. DOI: 10.2144/96214bm10. View

Zhang X, Potty A, Jackson G, Stepanov V, Tang A, Liu Y . Engineered 5S ribosomal RNAs displaying aptamers recognizing vascular endothelial growth factor and malachite green. J Mol Recognit. 2009; 22(2):154-61. DOI: 10.1002/jmr.917. View

Zhao Y, Tu M, Wang W, Qiu J, Yu A, Yu A . Genetically engineered pre-microRNA-34a prodrug suppresses orthotopic osteosarcoma xenograft tumor growth via the induction of apoptosis and cell cycle arrest. Sci Rep. 2016; 6:26611. PMC: 4877571. DOI: 10.1038/srep26611. View

Leader B, Baca Q, Golan D . Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov. 2007; 7(1):21-39. DOI: 10.1038/nrd2399. View

Davidson B, McCray Jr P . Current prospects for RNA interference-based therapies. Nat Rev Genet. 2011; 12(5):329-40. PMC: 7097665. DOI: 10.1038/nrg2968. View

Beckert B, Masquida B . Synthesis of RNA by in vitro transcription. Methods Mol Biol. 2010; 703:29-41. DOI: 10.1007/978-1-59745-248-9_3. View

Paige J, Nguyen-Duc T, Song W, Jaffrey S . Fluorescence imaging of cellular metabolites with RNA. Science. 2012; 335(6073):1194. PMC: 3303607. DOI: 10.1126/science.1218298. View

Ponchon L, Catala M, Seijo B, El Khouri M, Dardel F, Nonin-Lecomte S . Co-expression of RNA-protein complexes in Escherichia coli and applications to RNA biology. Nucleic Acids Res. 2013; 41(15):e150. PMC: 3753655. DOI: 10.1093/nar/gkt576. View

10.

Ho P, Yu A . Bioengineering of noncoding RNAs for research agents and therapeutics. Wiley Interdiscip Rev RNA. 2016; 7(2):186-97. PMC: 4769674. DOI: 10.1002/wrna.1324. View

11.

Bader A, Brown D, Winkler M . The promise of microRNA replacement therapy. Cancer Res. 2010; 70(18):7027-30. PMC: 2940943. DOI: 10.1158/0008-5472.CAN-10-2010. View

12.

Bader A . miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet. 2012; 3:120. PMC: 3387671. DOI: 10.3389/fgene.2012.00120. View

13.

Deng Y, Wang C, Choy K, Du Q, Chen J, Wang Q . Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies. Gene. 2014; 538(2):217-27. DOI: 10.1016/j.gene.2013.12.019. View

14.

Wang W, Ho P, Chen Q, Addepalli B, Limbach P, Li M . Bioengineering Novel Chimeric microRNA-34a for Prodrug Cancer Therapy: High-Yield Expression and Purification, and Structural and Functional Characterization. J Pharmacol Exp Ther. 2015; 354(2):131-41. PMC: 4518075. DOI: 10.1124/jpet.115.225631. View

15.

Silhavy D, Molnar A, Lucioli A, Szittya G, Hornyik C, Tavazza M . A viral protein suppresses RNA silencing and binds silencing-generated, 21- to 25-nucleotide double-stranded RNAs. EMBO J. 2002; 21(12):3070-80. PMC: 125389. DOI: 10.1093/emboj/cdf312. View

16.

Ponchon L, Dardel F . Recombinant RNA technology: the tRNA scaffold. Nat Methods. 2007; 4(7):571-6. DOI: 10.1038/nmeth1058. View

17.

Ha M, Kim V . Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014; 15(8):509-24. DOI: 10.1038/nrm3838. View

18.

Adams D, Cauquil C, Theaudin M, Rousseau A, Algalarrondo V, Slama M . Current and future treatment of amyloid neuropathies. Expert Rev Neurother. 2014; 14(12):1437-51. DOI: 10.1586/14737175.2014.983905. View

19.

Pereira P, Tomas J, Queiroz J, Figueiras A, Sousa F . Recombinant pre-miR-29b for Alzheimer´s disease therapeutics. Sci Rep. 2016; 6:19946. PMC: 4730146. DOI: 10.1038/srep19946. View

20.

Jin J, Cid M, Poole C, McReynolds L . Protein mediated miRNA detection and siRNA enrichment using p19. Biotechniques. 2010; 48(6):xvii-xxiii. DOI: 10.2144/000113364. View